GSK blows Jemperli marching horn against Keytruda with new …
WEBAug 1, 2024 · On Thursday, the FDA expanded the endometrial cancer use for GSK’s Jemperli, used in combination with chemotherapy, to include patients with mismatch repair proficient (pMMR) or...
Jemperli (dostarlimab) trial continues to show unprecedented ... - GSK
WEBJun 3, 2024 · GSK plc (LSE/NYSE: GSK) today announced updated, longer-term results from the phase II supported collaborative study with Memorial Sloan Kettering Cancer Center (MSK) evaluating Jemperli (dostarlimab) as a first-line treatment—as an alternative to surgery—for mismatch repair deficient (dMMR) locally advanced rectal cancer.
Jemperli (dostarlimab-gxly) plus chemotherapy approved in the …
WEBJul 31, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR ...
GSK’s Jemperli (dostarlimab) plus chemotherapy approved as the …
WEBDec 11, 2023 · GSK’s Jemperli (dostarlimab) plus chemotherapy approved as the first and only frontline immuno-oncology treatment in the European Union for dMMR/MSI-H primary advanced or recurrent endometrial cancer. Download (PDF, 195.8KB) European Commission also converts previous conditional approval for Jemperli to full approval as a monotherapy for ...
GSK, iTeos Score Phase II Win for Jemperli-TIGIT Combo in NSCLC
WEB5 days ago · In iTeos’ news release of the data drop, the partners called this effect a “clinically meaningful improvement,” noting that it represented an increase of around 30% versus Jemperli (dostarlimab) alone. ... Jemperli monotherapy counterparts, on the other hand, saw a 65% dip in circulating tumor DNA during this time frame. GSK and iTeos ...
FDA approves dostarlimab-gxly with chemotherapy for …
WEBOn July 31, 2023, the Food and Drug Administration approved dostarlimab-gxly (Jemperli, GlaxoSmithKline) with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for primary...
Jemperli (dostarlimab-gxly) trial continues to show …
WEBJun 3, 2024 · Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer ...
GSK's Jemperli/Chemo Combo Shows Response Rate Of 46% In …
WEBDec 7, 2022 · GSK plc (NYSE: GSK) announced results from the PERLA phase 2 trial investigating Jemperli (dostarlimab) + chemotherapy versus Merck & Co Inc's (NYSE: MRK) Keytruda pembrolizumab + chemo as a...
Glaxo's (GSK) Jemperli Gets FDA Approval for New Indication - Yahoo Finance
WEBAug 18, 2021 · The FDA grants accelerated approval to Glaxo's (GSK) Jemperli for treating patients with mismatch repair-deficient recurrent/advanced solid tumors. This is the second approved indication for the...
FDA Approves Immunotherapy for Endometrial Cancer with …
WEBApr 22, 2021 · Today, the U.S. Food and Drug Administration granted accelerated approval to Jemperli (dostarlimab) for treating patients with recurrent or advanced endometrial cancer that has progressed on or...